the aid library

LIST OPTIONS

Filter

8419

Status Report - WHO Collaborating Centres in the Americas, 2022

Pan American Health Organisation PAHO (2022) C_WHO

Updated 2 June 2022.# This entry contains the Status Report of WHO Collaborating Centres in the Americas by Country and a new document with information of Collaborating Centres by Outcome of the Strategic Plan of the Pan American Health Organization 2020‑2025.

Download (307)

View PDF (345)

Vaccine crisis communication manual: step-by-step guidance for national immunization programmes

World Health Organization WHO, Regional Office of Europe (2022) CC

Download (388)

View PDF (571)

Strategy to respond to antimalarial drug resistance in Africa

World Health Organization WHO (2022) C_WHO

The Strategy to respond to antimalarial drug resistance in Africa is a technical and advocacy document, grounded in the best available evidence to date and aimed at minimizing the threat and impact of antimalarial drug resistance of Plasmodium falciparum parasites in Africa. Its objectives are to: i... more

Download (1128)

View PDF (1088)

Eradication of yaws: a guide for programme managers

World Health Organization WHO (2018) C_WHO

This document provides guidance for countries on how to implement activities to achieve the interruption of yaws transmission. It is intended for use by national yaws eradication programmes, partners involved in the implementation of yaws eradication activities and WHO technical staff who provide te... more

Download (585)

View PDF (572)

Robson Classification: Implementation Manual

World Health Organization (2017) C_WHO

In 2015, WHO proposed the use of the Robson classification (also known as the 10-group classification) as a global standard for assessing, monitoring and comparing caesarean section rates both within healthcare facilities and between them. The system classifies all women into one of 10 categories t... more

Download (495)

View PDF (488)

Supporting the routine use of evidence during the policy-making process: a WHO checklist

World Health Organisation (WHO) (2023) C_WHO

This checklist is for any organization or person supporting the routine use of evidence in the process of policy-making. Evidence-informed policy-making (EIPM) is essential for achieving the Sustainable Development Goals (SDGs) and universal health coverage (UHC). Its importance is emphasized in WH... more

Download (316)

View PDF (421)

WHO global report on trends in prevalence of tobacco use 2000-2025

World Health Organization WHO (2021) C_WHO

Progress in reducing tobacco use is a key indicator for measuring countries’ efforts to implement the WHO Framework Convention on Tobacco Control – target 3.a under the Sustainable Development Goals agenda. Countries have adopted this indicator to report progress also towards the tobacco reducti... more

Download (425)

View PDF (493)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (520)

View PDF (737)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (726)

View PDF (1265)

Generic risk assessment model for insecticide-treated nets, 2nd ed.

World Health Organization (WHO) (2018) C_WHO

Long-lasting insecticidal nets (LNs) constitute a core vector control intervention against malaria. A number of new LN products are under development and will require assessment of risks to humans. This document provides an updated generic model that can be used for the risk assessment of exposure t... more

Download (494)

View PDF (713)

Model disability survey (MDS): survey manual

World Health Organization (WHO) & The World Bank (WB) WHO (2017) CC

The World Health Organization's Model Disability Survey (MDS) Manual is a tool to help implement the MDS in countries and to improve the quality of the interview process. This manual is intended to provide practical information about the survey instruments and their use during interviews. This manua... more

Download (246)

View PDF (365)

Q&A: Older people and COVID-19

World Health Organization WHO (2020) CC

Older people, and people of all ages with pre-existing medical conditions (such as diabetes, high blood pressure, heart disease, lung disease, or cancer) appear to develop serious illness more often than others. Here's how you can protect yourself.

Download (428)

View PDF (424)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (553)

View PDF (592)

The impact of myopia and high myopia

World Health Organization (WHO) (2017) C_WHO

Report of the Joint World Health Organization–Brien Holden Vision Institute Global Scientific Meeting on Myopia | University of New South Wales, Sydney, Australia 16–18 March 2015

Download (369)

View PDF (549)

Dual HIV/syphilis rapid diagnostic tests can be used as the first test in antenatal care

World Health Organization WHO (2019) C_WHO

Policy Brief. WHO recommends that pregnant women receive testing for HIV, syphilis and hepatitis B (HBSAg) at least once during pregnancy, preferably in the first trimester. Dual HIV/syphilis rapid diagnostic tests (RDTs) can be used as the first test for pregnant women as part of antenatal care (... more

Download (264)

View PDF (412)

HIV/AIDS treatment and care in Belarus

J. D. Lundgren; D. Raben; I. Eramova; V. Ilyenkova World Health Organization (Europe); Centre for Heath & Infectious Disease Research (2014) C_WHO

Evaluation report January 2014

Download (408)

View PDF (524)

The 12 Core Concepts for Understanding Traumatic Stress Responses in Children and Families Adapted for Youth Who Are Trafficked

The National Child Traumatic Stress Network (NCTSN) (2012) C2

The 12 Core Concepts for Understanding Traumatic Stress Responses in Children and Families provide a rationale for trauma-informed assessment and intervention. The Concepts cover a broad range of points that practitioners and agencies should consider as they strive to assess, understand, and assi... more

Download (390)

View PDF (413)

Toolkit for safe listening devices

World Health Organization WHO (2019) C_WHO

Download (293)

View PDF (412)

Preventing injuries and violence: an overview

World Health Organisation (WHO) (2022) C_WHO

This brief advocacy document highlights the burden, risks and prevention of injuries and violence, which took the lives of 4.4 million people in 2019 and constitute 8% of all deaths. Among the injury-related causes of death include road traffic crashes, drowning, falls, burns, poisoning and violence... more

Download (1593)

View PDF (2239)

Preventing Diarrhoea through Better Water, Sanitation and Hygiene

Jamie Bartram, Sandy Cairncross, Thomas Clasen et al. World Health Organization (WHO) (2014) C_WHO